Veno-occlusive disease of the liver during induction therapy for acute lymphoblastic leukemia.
Veno-occlusive disease (VOD) of the liver, also termed as sinusoidal obstruction syndrome, constitutes a well-known complication of high-dose cytoreductive chemotherapy prior to allogeneic or autologous bone marrow transplantation and is associated with the intensity of treatment [1]. On the contrary, there is only one report of VOD during induction therapy for acute lymphoblastic leukemia in a patient with Marfan syndrome, who was successfully treated with defibrotide [2]. In this article, we present the first fatal case of VOD during induction therapy for acute lymphoblastic leukemia.
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece.
Athanasios
A
Papadopoulos
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece. ntaiosgeorge@yahoo.gr.|S. Kiriakidi 1, AHEPA Hospital, 54636, Thessaloníki, Greece. ntaiosgeorge@yahoo.gr.
George
G
Ntaios
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece.
Georgia
G
Kaiafa
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece.
Fotios
F
Girtovitis
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece.
Zoi
Z
Saouli
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece.
Zisis
Z
Kontoninas
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece.
Michael D
MD
Diamantidis
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece.
Christos
C
Savopoulos
First Propedeutic Department of Internal Medicine, AHEPA Hospital, Aristotle University, Thessaloníki, Greece.
Apostolos
A
Hatzitolios
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D008382:Marfan Syndrome / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011089:Polydeoxyribonucleotides / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D014750:Vincristine; D011239:Prednisolone; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin